Naked plasmid DNA (pDNA) vaccine expressing herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) was tested for protective activity against acute HSV-1 infection in mice. The pDNA was intravenously injected into Balb/c mice via their tail vein under high pressure, and the vaccination was performed two times at an interval of 7 days. The gB gene vaccination significantly protected the mice from subsequent intraperitoneal challenge with a lethal dose of HSV-1, which killed all the animals given control plasmid or saline. The protective activity was correlated with the dose of the plasmid inoculated, the survival rate reaching 83% in mice vaccinated with 5 mg of pDNA. The vaccinated mice were also protected from latent HSV infection. The immunized mice showed significant elevation in neutralizing antibody against HSV-1 as well as serum levels of interleukin-12 (IL-12) and interferon-g (IFN-g). When mice were immunized with 5 mg of an Epstein-Barr virus (EBV)-based plasmid vector harboring the gB, the cytotoxic T lymphocytes (CTLs) activity and proliferative response for HSV-1 were also induced. The results strongly suggest that intravenous immunization of naked pDNA may induce humoral and cellular immune responses against the virus, leading to a significant prophylactic outcome against HSV-1 infection in mice.
Introduction
The genetic vaccination is expected to provide novel preventive means against infectious diseases that are fatal, severe, or highly epidemic. 1 The naked plasmid DNA (pDNA) transfection is a suitable method to transfer genetically antigen in vivo. As muscle cells are capable of taking up plasmid DNA and expressing exogenous genes, 2 the skeletal muscle is regarded as a good target organ to be genetically immunized. 1 Recently, it was shown that extremely strong expression of transgene is achieved by intravenously injecting naked pDNA into mice via the tail vein under high pressure (the hydrodynamics-based procedure). 3, 4 The procedure may greatly expand the potential of naked pDNA transfer for practical use including gene therapy and genetic vaccination. We have previously shown that use of an Epstein-Barr virus (EBV)-based plasmid vector that harbors the EBV nuclear antigen 1 (EBNA1) gene and oriP sequence further improved the hydrodynamics-mediated transfection, in terms of the transfer efficiency as well as magnitude and longevity of expression. 5 The herpes simplex viruses cause a variety of clinical illnesses that are painful and often distressing. 6, 7 These include oral-facial, genital, ocular, and cutaneous herpes, herpes encephalitis, neonatal herpes, and erythema multiforme. After establishment of primary infection, the pathogen produces latent and recurrent lesions, most commonly in the face and genitalia. Recurrent infection in the eyes could cause severe results such as blindness. It is desired to devise an effective vaccine that limits the frequency and severity of herpetic lesions. In this regard, the capability of the vaccine to stimulate virus-specific cytotoxic T lymphocytes (CTLs), CD4
þ T cells and antibody production is important. 6, 7 The glycoproteins D (gD) and B (gB) are important components of the HSV-1 envelope, participating in cell attachment and penetration. 8 They are also expressed on the surface of the infected cells during the early stages of HSV-1 infection. Since the glycoproteins harbor several T-and B-cell epitopes, most immunological and virological studies on HSV-1 focus on these antigens that are primary inducers and targets of both humoral and cellmediated immune responses. [6] [7] [8] [9] [10] [11] [12] [13] In this study, the HSV-1 gB gene is transfected into mice by means of the intravenous pDNA transfection to assess whether the efficient delivery system is also useful for genetic vaccination against an infectious disease. Antivirus immune responses induced by the vaccination are also analyzed.
Results
Intravenous pDNA immunization protected mice from lethal HSV-1 challenge
We first examined whether intravenous vaccination of naked pDNA encoding an antigen gene induces prophylactic effects in mice against acute viral infection. An expression plasmid carrying the HSV-1 gB gene was constructed (pG.gB) (Figure 1) , and various amounts of the plasmid were used for intravenous vaccination of mice. Following systemic inoculation of a lethal dose of HSV-1, all the control mice sham-immunized with sterile saline died by day 10 ( Figure 2b ). In sharp contrast, 83.3% of mice given injections with 5 mg of pG.gB survived the HSV-1 challenge. The protective effects depended on the dose of the plasmid, as suggested by the survival rates of mice immunized with 3 or 1 mg of pG.gB (33.3 and 16.7%, respectively).
The authors also constructed another plasmid vector that contains the gB gene expression unit as well as the EBNA1 gene and oriP (pGEG.gB) (Figure 1) , and assessed its efficiency as a intravenous vaccine. Again, all the control mice given injections of saline died by day 10, while dose-dependent protective effect was demonstrated in mice immunized with 5, 3, and 1 mg of pGEG.gB (survival rates were 83.3, 66.7, and 16.7%, respectively) ( Figure 2a ). However, any significant difference was not demonstrated between mortality rates of pGEG and pG groups.
As HSV causes latent infection in the sensory ganglia, we examined whether the DNA vaccination protected mice from the latent HSV infection. The PCR analysis did not show any evidence for HSV viral persistence in the trigeminal ganglia from mice that survived the acute HSV infection after pGEG.gB immunization ( Figure 3 ).
Induction of HSV-1 neutralizing antibodies
To elucidate the mechanisms that led to the protective outcomes, immune responses against HSV-1 were examined. First, neutralizing antibody against the virus was measured. Mice were vaccinated with pDNAs as above, and their sera were subjected to the plaque reduction assay. As shown in Figure 4a , the immunization of 5 mg of pG.gB or pGEG.gB induced strong neutralization activities that were not detected in pGEG.luc or saline control groups. The groups given 1 mg of pG.gB or pGEG.gB also showed inhibition activities against HSV-1 plaque formation, but the inhibition rates were significantly lower than those of groups given 5 mg of pDNAs. Titers of neutralizing antibodies were also evaluated. As shown in Figure 4b , both pGEG.gB and pG.gB immunization induced high titers of neutralizing antibodies against HSV-1. The data are consistent with the results shown in Figure 4a , demonstrating that the intravascular gB genetic vaccine effectively elicited neutralizing antibody production in mice. show a significant increase in killing activity against P815.gB ( Figure 5a ). The results demonstrated that the intravenous vaccination with 5 mg of pGEG.gB elicited specific cell-mediated immune responses that, at least partly, may have contributed to viral clearance. Proliferative response for HSV was also tested. The spleen cells obtained from pGEG.gB-immunized mice showed significant proliferation in the presence of UVinactivated HSV, while pG.gB immunization failed to induce HSV-specific proliferative response (Figure 4c ).
Elevation in the serum cytokine levels in gB gene-immunized mice
To examine whether pDNA immunization influenced systemic production of cytokines, we measured the serum concentrations of IL-12 and IFN-g in mice immunized with the antigen gene. The ELISA analysis demonstrated that both cytokines were drastically elevated in serum levels after the gB gene immunization ( Figure 6 ). The concentrations of the cytokines were virtually the same in vaccinated mice regardless of the doses and plasmids. It is suggested that the cytokine production may reach plateau after administrations of a relatively small amount of plasmid in this vaccine system. The immunization of pGEG.Luc did not induce significant cytokine production, suggesting that the cytokine responses induced by the gB plasmids were not due to the CpG motifs. The results suggest that Th1 immune response was augmented in the mice having received the intravenous gB genetic vaccination.
Discussion
The present study demonstrated that the intravascular immunization of gB expression plasmid significantly protected mice from subsequent intraperitoneal infection of a lethal dose of HSV-1. The hydrodynamics-based procedure was applied to transduce mice with a1-antitrypsin 14 and factor IX 14, 15 genes, suggesting the potential usefulness of the system in controlling hereditary diseases. Lui et al 16 as well as the authors 17, 18 delivered cytokine genes to the mice that had been implanted with syngenic tumor cells, resulting in significant suppression of the solid 16 or metastatic 17,18 35 or the granulocyte-macrophage colony stimulating factor (GM-CSF) 6 is employed as an adjuvant in combination with the pDNA vaccine. An alternative method to enhance the cellular immune response is the use of antigen presenting cells (APCs) such as the dendritic cells (DCs), 6 ,36,37 macrophages 6 or keratinocytes 13 that have been engineered ex vivo to express the glycoprotein gene. In the present study, we have shown that intravenous vaccination of a high dose of EBV-based pDNA enhanced not only antibody but also CTL activity. The antigen may be relatively easily accessible to and loaded into professional APCs, when the genetic vaccine is administered through the intravascular route. Intramuscular vaccine usually requires 2-3 weeks from the last immunization to reach full potential, 38, 39 while in the present intravascular vaccination system, remarkable protection effect was obtained 3 days after the last immunization (Figures 2 and 3) .
It is well established that both humoral (Th2/antibody) and cellular (Th1/CTL) responses play crucial roles in the control and clearance of HSV infection in human. 7, 11, [40] [41] [42] [43] [44] The former may contribute to blocking the spread of extracellular virus particles and neutralizing their ability to infect cells, while the latter recognizes and eliminates infected cells. Live or attenuated HSV vaccine is capable of inducing both antibody and CTL responses. 7 Although humoral responses induced by intramuscular pDNA vaccine protocols protect animals from acute HSV infection, 8, [26] [27] [28] [29] [30] [31] effectiveness of these strategies in controlling latent and recurrent infection has not been elucidated. The cellular immune responses may play important roles in antivirus defense, in case genetic vaccine will be applied to humans. The intravascular pDNA vaccination could provide a useful model system to reveal the molecular and cellular mechanisms that generate cell-mediated immune responses against pathogens.
In this concern, the present system suggests that the neutralizing antibody predominantly contributed to the protection from acute infection, because the survival rates did not correlate with cellular immune responses (Figures 2, 4c and 5) . Immunization of 5 mg of pG.gB, for example, elevated neither CTL activity nor proliferative response, but protected 80% of mice from lethal challenge of the virus. Previous studies on intramuscular genetic vaccination also demonstrated that humoral immune responses mainly contributed to the protection from acute infection. 8, [26] [27] [28] [29] [30] [31] An intravenous genetic vaccine was tested by Rogers et al 44 who, instead of naked pDNA, combined a gD expression vector with a synthetic macromolecule, asialoorosomucoid poly-L-lysine. The gD antigen was expressed in the parenchymal and nonparenchymal cells of the liver of the injected mice. Significant infiltration of CD4 þ T cells was demonstrated in the liver, although neither the Th1 nor CTL activity was examined.
In the present study, vaccination of 5 mg of the EBVbased plasmid significantly enhanced CTL activity and proliferative response, while injection of the conventional plasmid vector failed to do so. This is consistent with our previous finding that the hydrodynamics-based transfection of EBV-based plasmid vectors resulted in strong and prolonged expression of marker genes. 5 When EBV-based or conventional plasmid vectors with the firefly luciferase gene were transferred, the former induced approximately 1.5, 8, and 100 times higher expression of the marker gene in the liver than did the latter, at 8 h, 24 h, and 30 days after the injection, respectively. 5 Similar results were also obtained by transferring cytokine genes 17, 18 (Kishida et al and Itokawa et al, manuscripts in preparation). The highlevel expression obtained by the EBV-based plasmid vectors may be ascribed to multiple functions of EBNA1, which binds oriP in a sequence-specific manner facilitating nuclear transfer of the plasmid 46, 47 binding of the plasmid to the nuclear matrix, 48 and transcriptional enhancement. [49] [50] [51] Taking advantage of the high transfection efficiency both in vitro and in vivo, we have applied the EBV system to a variety of preclinical gene therapy trials against malignant, 52-59 chronic, 59 ,60 and genetic diseases. 59, 61, 62 The EBV-based plasmids, however, have never been utilized for the genetic immunization against an infectious disease.
In conclusions, the present study demonstrated that the intravascular transfection of naked pDNA provides a quite efficient means to induce protective immunity in mice. The system may also offer powerful strategies to screen and analyze putative antigens/epitopes of a pathogen of interest, generating useful information to devise novel and effective vaccine.
Materials and methods

Plasmid vectors
The gB coding sequence was PCR-amplified from the Miyama strain of HSV-1 DNA using a pair of sense (5 0 -cgtagtcccgccatgcgcca-3 0 ) and antisense (5 0 -aaccccccat cacaggtcgt-3 0 ) primers. The fragment was inserted into pGEG.4 or pG.4 vectors 5 to construct pGEG.gB and pG.gB plasmids. Briefly, pGEG.gB contains a CAG promoter 63 upstream of the gB coding sequence, EBV oriP 64 EBV EBNA-1 gene 64 driven by another CAG promoter, the ampicillin-resistant (Amp R ) gene, and the replication origin for E. coli (Figure 1, upper left panel) . The pG.gB contains the CAG-gB, Amp R gene, and ori ( Figure 1, upper right panel) . pGEG.luc harbors a firefly luciferase gene as described (Figure 1, lower panel) . 55 Plasmids were purified using Qiagen Maxiprep Endofree kits (Qiagen, Hilden, Germany).
Cells and virus
The Miyama strain of HSV-1 44 was plaque-purified, grown on Vero cell monolayers, and stored in aliquots at À801C. Titers were measured in Vero cells and Intravascular naked DNA vaccine against HSV-1 F-D Cui et al expressed as plaque forming unit (PFU)/ml. P815 cells were maintained in RPMI 1640 medium (Nacalai Tesque, Kyoto, Japan) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal bovine serum (FBS). P815.gB cells were established by cotransfecting P815 cells with pG.gB and pAmpNeo, a neomycinresistant gene expression plasmid, followed by G418 selection.
Mice, immunization, and infection
Female Balb/c mice were purchased from Shimizu Laboratory Suppliers Co. Ltd (Kyoto, Japan). They received humane care in compliance with the Guide to the Care and Use of Laboratory Animals. Mice (8-weekold) were intravenously injected into their tail vein with 1.6 ml plasmid solution within 5 s. The immunization was performed two times on days 0 and 7. At 3 days after the secondary immunization, mice were infected with HSV-1 by injecting 0.1 ml of viral suspension (10 5 PFU/ml) into the peritoneal cavity.
Detection of latent infection
Latent infection of HSV-1 was assessed as described. 65 Briefly, DNA was extracted from trigeminal ganglia, cerebrum, and cerebellum of mice. PCR was performed using a pair of sense (5 0 -atccgaacgcagccccgctg-3 0 ) and antisense (5 0 -tctccgtccagtcgtttatcttc-3 0 ) primers that are specific for the HSV glycoprotein D coding sequence (denaturation at 941C for 1 min, annealing at 601C for 1 min, extension at 721C for 1 min) (35 cycles). The PCR products were separated by gel electrophoresis through 2% agarose gel, followed by ethidium bromide staining.
Proliferative response for HSV
Mice were immunized with 5 mg of the pGEG.Luc, pGEG.gB, or pG.gB on days 0 and 7. On day 21, mice were killed and spleen cell suspensions were prepared. The cells were seeded into 96-well plates at a density of 2 Â 10 5 /well, and cultured with or without 3 Â 10 5 PFU/ well of UV-inactivated HSV-1 for 3 days. 
Cytotoxicity assays
As effector cells, splenic cells were obtained from the immunized mice 3 days after the secondary immunization. A total of 10 million spleen cells were cocultured for 7 days with 1 Â 10 6 of the P815.gB cells that had been X-ray-irradiated at a dose of 40 Gy, in the presence of 2 IU/ml of recombinant IL-2. The target cells (P815 and P815.gB) were incubated with 370 kBq Na 2 51 CrO 4 for 60 min at 371C. After washing, the target cells were seeded into microtiter plates at a density of 1 Â 10 4 /well. The effector cells were added into the plates at various effector to target (E:T) ratios. After 4 h of incubation at 371C in 5% CO 2 /95% humidified air, supernatants were collected and radioactivity was measured on a gamma counter. Specific 51 Cr release was calculated according to the standard formula. 55 
ELISA
Sera were obtained from the carotid artery of mice 3 days after the last immunization. Cytokine concentrations in the sera were assayed using mouse IL-12 (BioSource International, Camarillo, CA, USA) and IFN-g (BioSource International, Camarillo, CA, USA) ELISA kits according to the supplier's instructions.
Neutralization assays
The neutralizing activity in mouse serum was analyzed by a plaque reduction assay in Vero cells. 42 Briefly, sera were obtained from mice 3 days after the last immunization. After heat-inactivated at 561C for 30 min, the sera were diluted 1:10 in DMEM/2% heat-inactivated FBS and delivered to duplicate wells of 96-well plates, into which 50 ml of HSV-1 suspension (4000 PFU/ml) was subsequently added. The plates were incubated overnight at 41C, before Guinea pig complement (Harlan, Loughborough, UK) diluted 1:4 in DMEM/2% heatinactivated FBS was added to each sample well. After incubation for 1 h at 371C, 50 ml of serum-free medium was added and the resultant mixture was used to infect confluent Vero cells in 24-well plates (Costar). After incubation for 1 h at 371C, cells were washed and overlaid with 1 ml of DMEM containing 5% heatinactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2% methylcellulose, followed by further incubation for 48 h under the standard condition. Fixed with 2.5% glutaraldehyde, cells were stained with 0.5% methylene blue for 30 min to visualize plaques.
To evaluate the titers of the neutralizing antibodies, sera were obtained from mice 26 days after the last immunization. The pooled serum samples were diluted 1:10 in PBS, followed by preparation of serial two-fold dilutions (1:10 to 1:1280). The neutralization was performed as above. Neutralizing titer was defined as the reciprocal of the highest dilution of serum to produce a 50% reduction in the number of plaques. 32 
Statistical analyses
For the ELISA, cytotoxicity, proliferation, and neutralizing assays, Student's t-test was used. The survival differences between groups were evaluated using logrank test.
